Seroquel 50%

Quick links to important sections

Seroquel 50%

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Seroquel 50%

Quick Facts

Property Description
Active ingredient Quetiapine (as fumarate salt)
Form Oral tablet (Immediate-Release and Extended-Release)
Pharmacological Class Atypical Antipsychotic (Second-generation Antipsychotic)
General Purpose Supporting the stabilization of mood and thought processes
Origin Synthetic, Dibenzothiazepine derivative

What is Seroquel and Its Pharmacological Class?

Seroquel is a medicinal product containing the active ingredient Quetiapine, a synthetic compound classified as an atypical antipsychotic agent, widely known as a Second-generation antipsychotic (SGA). It is formally recognized as a psychotropic agent due to its targeted action within the central nervous system. The chemical structure of Quetiapine places it within the dibenzothiazepine derivative family, confirming its manufactured origin and specialized function. Quetiapine is classified as an SGA, a designation based on its differential mechanism compared to older classes.


Composition and Available Forms of Quetiapine

The composition of this medication is based on Quetiapine fumarate, which is the form of the active substance used in the preparation of the oral tablet. This product is a single-ingredient product, containing only Quetiapine and the necessary inert excipients to form the tablet matrix for oral administration. Quetiapine tablets are commonly manufactured in two distinct pharmaceutical forms: an immediate-release (IR) formulation and an extended-release (ER) formulation. The availability of both IR and ER forms is a differentiating factor of the compound, allowing for varied absorption profiles.


General Therapeutic Role of Atypical Antipsychotics

The general therapeutic purpose of Quetiapine is to support the stabilization of emotional and mental processes by modulating key brain chemicals. As an SGA, it functions by regulating the activity of neurotransmitters, specifically dopamine and serotonin, which are crucial for mood, perception, and behavior. Atypical antipsychotics function by adjusting the levels of brain chemicals to support the stabilization of complex mental health conditions. This approach is fundamentally directed at restoring neurochemical equilibrium.

What side effects are possible with Seroquel 50%?

Possible Side Effects and Safety Information

Quetiapine's official safety profile, as documented in regulatory texts like the FDA Prescribing Information and the EMA Summary of Product Characteristics, outlines potential adverse reactions categorized by frequency and the body system affected. These classifications communicate the documented risk profile of the medication without providing clinical advice.

Frequency-Classified Adverse Reactions

The most frequently documented side effects in adult patients are classified as Very Common (occurring in ge 10% of patients). These typically include somnolence (drowsiness), dizziness, and dry mouth. Effects classified as Common (occurring in ge 1% to <10% of patients) include weight gain, constipation, tachycardia (rapid heart rate), orthostatic hypotension (dizziness upon standing), and increased blood sugar levels (hyperglycemia).

Serious Adverse Reactions and Safety Constraints

The regulatory labeling includes specific warnings for medically significant events. A mandatory Boxed Warning highlights the increased risk of mortality when atypical antipsychotics, including quetiapine, are used in older adults with dementia-related psychosis; use for this condition is not approved. An increased risk of suicidal thoughts and behaviors is also noted in children, adolescents, and young adults taking the medication for depression. Other serious events officially documented include Neuroleptic Malignant Syndrome (NMS), severe metabolic changes (including diabetes mellitus and dyslipidemia), and the development of Tardive Dyskinesia, a syndrome of involuntary movements.

Contextual Safety Patterns

The time of onset for certain effects is documented; for example, somnolence and orthostatic hypotension often appear during the initial dose-titration period. Conversely, conditions like Tardive Dyskinesia and Cataracts are noted as potential concerns associated with long-term exposure. Safety constraints include a formal contraindication for known hypersensitivity to the drug's components.

Overdose and Emergency Response

Overdose and When to Seek Help

A Quetiapine overdose requires immediate medical attention, as the official regulatory guidance confirms no specific antidote is known to reverse its effects. Patients or caregivers are mandated to contact emergency services or a Poison Control Center right away for any suspected overdose. The management approach is restricted to symptomatic and supportive treatment to stabilize the patient, as defined in the official prescribing information.

Documented clinical manifestations of overdose primarily involve Central Nervous System (CNS) depression, presenting as profound somnolence, delirium, and progression to coma. Cardiovascular signs often include tachycardia (rapid heart rate) and hypotension (low blood pressure). Severe outcomes reported in official documentation include seizures, respiratory depression (difficulty breathing), QT prolongation, and, in the most critical cases, fatal outcomes (death).

Official guidelines require continuous cardiovascular monitoring to detect serious arrhythmias and recommend maintaining a patent airway to ensure adequate ventilation. Regulatory information notes that elderly patients with dementia-related psychosis have an increased risk of severe outcomes, which is a factor relevant to the severity of an overdose scenario. Procedures such as gastric lavage and activated charcoal may be considered by healthcare professionals in instances of severe intoxication soon after ingestion.

Therapeutic Uses of Seroquel 50%

What Seroquel Treats: Main Uses and Benefits

This medication is commonly used to help manage symptoms across major psychiatric domains. It is applied in situations involving certain distressing symptoms, generally contributing to easing the overall symptom load and supporting patient stability.

This medication is applied across therapeutic domains, including Schizophrenia, Bipolar I Acute Manic Episodes, Bipolar Depressive Episodes, and as an adjunct treatment for Major Depressive Disorder. It supports management in clinical scenarios ranging from the rapid handling of acute psychosis to long-term relapse prevention.

Focus on Symptom Relief

This medication is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as the thought disorganization of psychosis, the hyperactivity of mania, and the low mood of depression. It is relevant for easing symptoms like hallucinations, delusions, and extreme mood swings.

“The supportive relief helps patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability.”


Quick Fact: Relief for Thought and Mood Symptoms

  • Target Symptoms: Hallucinations, Delusions, Acute Mania, Bipolar Depression.
  • Clinical Goal: Supports a more coherent state of mind and contributes to achieving a more settled mood state.
  • Context: Used as monotherapy for core conditions and as adjunctive support for complex depressive illness.

Eligibility and Restrictions for Use

Who Can and Cannot Use Quetiapine (Seroquel)

The official eligibility profile for Quetiapine is defined by regulatory documents, establishing which populations are approved for use and which are explicitly restricted or contraindicated.

Eligibility Scope

Scope Item Official Regulatory Status
Populations for whom use is allowed Adults (18+ years). Adolescents 13–17 (Schizophrenia) and 10–17 (Bipolar Mania). Patients with Renal Impairment (no dose adjustment necessary).
Populations for whom use is not recommended Children and adolescents below 18 (general EMA guidance). Nursing mothers (breastfeeding is not recommended).
Populations for whom use is contraindicated Patients with known Hypersensitivity to Quetiapine or any component. Patients receiving concomitant strong CYP3A4 inhibitors. Elderly patients with dementia-related psychosis (due to increased mortality risk).

Eligibility-Related Restrictions

Official labeling mandates conditional use for several groups. Use requires caution in all elderly patients and those with pre-existing Cardiovascular or Cerebrovascular disease. Patients with Hepatic Impairment are eligible but require a restricted starting dose and slower titration. The drug is not approved for children under 10 years of age.

What should I know about interactions with other medicines?

The interaction profile of Quetiapine is determined by documented effects on metabolism and the additive influence on the central nervous system (CNS).

Pharmacokinetic Interactions (Drug Exposure)

Quetiapine is primarily metabolized by the CYP3A4 enzyme. Co-administration with other substances that affect this enzyme leads to significant changes in drug concentration, as formally stated in regulatory labels:

  • Strong Inhibitors (e.g., ketoconazole, ritonavir) decrease clearance, resulting in substantially increased plasma concentrations. Specific mandatory dose adjustments are required by regulatory authorities.
  • Strong Inducers (e.g., phenytoin, carbamazepine) increase clearance, resulting in significantly reduced exposure.

Restrictions and Other Documented Interactions

The following interaction patterns are officially noted:

  • Food: The Extended-Release formulation must be taken without food or with a light meal (300 calories or less) to prevent a documented increase in drug absorption.
  • Pharmacodynamic Effects: Co-administration with alcohol or other centrally acting drugs results in additive CNS depressant effects, such as increased sedation.
  • Substance Interference: Grapefruit juice and the herbal supplement St. John's wort are documented to alter drug exposure through the CYP3A4 pathway and should be avoided.
  • Population Note: Patients with hepatic impairment exhibit decreased clearance, a population-specific consideration impacting overall drug exposure.

Mechanism of Action

Selective Neurotransmitter System Modulation

Quetiapine achieves its action by broadly blocking central receptors, primarily the Dopamine D2 ( DA2) and Serotonin 5-HT2 A receptors. The drug's higher binding strength to the 5-HT2 A receptor relative to the D2 receptor leads to a selective modulation of the dopamine system in key brain circuits . This action alters the strength of specific signaling cascades and leads to a shift in the ratio of neurotransmitter activity within neural pathways.


Triple Monoamine and Autonomic Pathway Regulation

The core mechanism is significantly enhanced by the active metabolite, Norquetiapine, which acts to inhibit the Norepinephrine Transporter ( NET) and partially stimulate the 5-HT1 A receptor. This combined activity regulates dopamine, serotonin, and norepinephrine availability. Additionally, the rapid blockade of Histamine H1 and alpha1 adrenergic receptors modulates central histaminergic and adrenergic tone, and influences autonomic activity, influencing the total physiological consequences of the drug's action.

Dosage and Administration Information

How Quetiapine is Used in Clinical Practice

Quetiapine is administered through oral tablet formulations, which include immediate-release (IR) and extended-release (ER) versions. The administration protocol typically involves a titration schedule during the initial phase of treatment. During this period, the dose is progressively increased over the first few days or week until a maintenance dose range, typically between 150 mg/day and 800 mg/day, is achieved.

Dosing Frequency and Constraints

The frequency of administration depends on the specific formulation used. The IR tablet is generally taken in divided doses, usually two or three times daily. In contrast, the ER tablet is intended for once-daily administration, typically taken in the evening. There are specific considerations regarding food intake: the IR tablet can be taken with or without food, whereas the ER tablet is taken either without food or with a light meal to support proper release kinetics.

Procedural and Population-Specific Rules

Specific protocols apply to different patient populations and tablet types. For older adults and individuals with hepatic impairment, treatment often begins with a lower starting dose, such as 25 mg/day or 50 mg/day, followed by a slower titration schedule. Regarding the integrity of the medication, ER tablets must be swallowed whole and must not be split, chewed, or crushed, as this is necessary to maintain their controlled-release functionality. If a dose is missed, the standard procedure is to take the next dose at the regularly scheduled time without doubling the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Seroquel 50%

Evidence for Use in Schizophrenia

The core research for this context has involved short-term, randomized controlled trials (RCTs) against placebo, and studies that included other treatments as comparators. These studies were used in research exploring how symptoms change over time, focusing on outcomes related to positive and negative symptoms and measurements of overall illness severity in the observed populations, including adults and adolescents (ages 13–17). For longer durations, studies monitored patient outcomes related to tracking recurrence over intermediate time intervals.

Evidence for Use in Bipolar Disorder and MDD

Research for bipolar disorder and Major Depressive Disorder (MDD) is separated by phase and context. Short-term, controlled trials have examined the compound as a single treatment (monotherapy) for acute manic episodes and bipolar depressive episodes, as well as an adjunctive treatment alongside other established mood stabilizers for both mania and MDD. Research examined outcomes related to episodic or acute changes using standardized scales like the MADRS and YMRS, with maintenance trials monitoring the occurrence of mood events over time.

Long-Term Data and Uncertainties

Evidence in special populations is primarily limited to adolescents. Certainty remains low for long-term outcomes in adolescents, as comparative evidence is lacking. The broader evidence base, while covering multiple indications, has known limitations, including: follow-up durations were limited (often 6 to 8 weeks) in the primary acute trials, restricting knowledge about long-term symptom patterns; data for certain patient groups remain insufficient; and long-term outcomes related to daily functioning are not fully established. Research is ongoing to address certain evidence gaps.

Key Studies & References

  1. Quetiapine monotherapy for bipolar depression: a systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Seroquel 50% (FAQ)


Q: Is 50 mg of Seroquel considered a low dose for its primary uses?

Official regulatory documents indicate that the typical maintenance dose for the drug's approved uses generally ranges much higher, often between 150 mg and 800 mg per day. The 50 mg amount is cited as a starting dose in the initial treatment schedule, and specifically as a starting dose for certain patient groups, such as older adults or those with liver problems.


Q: What is the common reason Seroquel 50 mg is prescribed?

According to official product information, the 50 mg amount is primarily used as a starting dose when initiating treatment for its approved uses, such as schizophrenia or bipolar disorder. Regulatory documents also specify this dose as the starting point for patients who may require slower dose adjustments, including the elderly or those with hepatic (liver) impairment.


Q: How quickly do the effects of Seroquel 50 mg typically start to be noticed?

The drug is rapidly absorbed by the body, reaching peak concentration within a few hours. Official documents note that some effects, such as drowsiness and dizziness upon standing (orthostatic hypotension), often appear during the very first days of treatment, which is known as the initial dose titration period. The time frame for therapeutic effects (changes in symptoms) is not specifically timed in the official documents.


Q: What are the most commonly reported physical side effects of Seroquel?

Official regulatory prescribing information lists the most common adverse reactions reported in clinical trials. These often include physical effects such as somnolence (drowsiness), dizziness, dry mouth, constipation, and tachycardia (a rapid heart rate).


Q: Is weight gain a documented side effect of Seroquel 50 mg?

Yes, weight gain is a common side effect documented in regulatory documents. Official guidelines note that weight should be monitored over time for patients taking this medication. The product information does not isolate the documented risk of weight gain specifically to the 50 mg dose, but rather to the drug overall.


Q: Can Seroquel 50 mg affect heart rate or heart rhythm?

Yes, regulatory documents note that tachycardia (rapid heart rate) is a common adverse reaction. There are also warnings regarding QT prolongation (an effect on the heart's electrical rhythm) reported in cases of overexposure or when the drug is combined with other risk factors/drugs. Official information states that the heart may require monitoring in specific circumstances.


Q: Are there known effects of Seroquel on blood pressure?

Yes, orthostatic hypotension is a common adverse reaction noted in the official product information. This refers to a drop in blood pressure when moving from sitting or lying down to a standing position, which can lead to dizziness or fainting. This effect is often more prominent when first starting the medication.


Q: Is it common for people to report feeling restless or having difficulty sitting still when taking Seroquel?

Regulatory texts list a condition called akathisia as a potential undesirable effect. Akathisia is a subjective feeling of inner restlessness and an urge to constantly move. Official sources classify this as a common or uncommon side effect depending on the patient group and the primary indication for which the drug is being used.


Q: Is the increase in appetite sometimes reported with Seroquel a temporary or long-term effect?

Official prescribing information lists increased appetite as a common side effect, which is related to documented weight gain observed in studies. While the documents confirm the effect and recommend monitoring, they do not explicitly define whether the increase in appetite is temporary or continues throughout the duration of use.


Q: How is Seroquel processed and cleared from the body, for example, by the liver or kidneys?

The drug is primarily processed in the body by the CYP3A4 enzyme in the liver. Less than 1% of the drug is excreted unchanged through urine. Due to this process, dose adjustment is specifically required for patients with hepatic (liver) impairment, but typically not for those with kidney (renal) problems.


Q: Is it true that Seroquel may increase the risk of certain blood problems?

Official regulatory labels caution about the risk of certain blood disorders. These include leukopenia and neutropenia (low white blood cell counts). In rare cases, a potentially fatal condition called agranulocytosis has been reported. Monitoring of blood cell counts is noted as necessary for patients with a pre-existing low white blood cell count.


Q: Is Quetiapine considered a medication with potential for physical dependence?

The official label notes that Quetiapine is not listed as a controlled substance under the U.S. Controlled Substances Act. However, the label does include a section on Drug Abuse and Dependence, noting that some patients have experienced misuse and that withdrawal symptoms have been reported when the drug is stopped.


Q: Do the sedative effects of Seroquel tend to decrease over a long period of use?

The official product information notes that the sedative effect, or somnolence (drowsiness), is often most prominent during the initial dose titration period, consistent with the possibility that the effect may lessen over time.


Q: Is it documented that Seroquel can cause problems with eyesight, such as cataracts?

Yes, official regulatory documents state that lens changes (cataracts) have been observed during long-term treatment with the drug. For this reason, the label indicates that a lens examination should occur when starting treatment and periodically throughout chronic use.


Q: What are the documented symptoms if Seroquel is stopped suddenly?

Regulatory documents state that acute withdrawal symptoms have been reported following the sudden discontinuation of the drug. These documented symptoms include insomnia (difficulty sleeping) and nausea. Official guidance indicates that the dose should be gradually reduced upon cessation.


Q: What information is available regarding the use of Seroquel during pregnancy?

Official information states that limited human data is currently available regarding its use during pregnancy. However, the label notes that neonates exposed to the drug during the third trimester are at risk for extrapyramidal (movement) and/or withdrawal symptoms after delivery. Official documents state that use during pregnancy should occur only if the potential benefit justifies the potential risk to the fetus.


Q: Does Seroquel affect thyroid function or hormone levels?

Yes, the regulatory label documents the potential for the drug to affect certain hormonal systems. These documented effects include the possibility of hypothyroidism (low thyroid hormone levels) and hyperprolactinemia (increased levels of the hormone prolactin), both of which may require clinical monitoring.


Q: What type of monitoring is recommended for patients taking Seroquel long-term?

Official guidance documents recommend several long-term monitoring checks due to documented safety concerns. This includes monitoring for symptoms of diabetes, performing fasting blood lipid testing (for cholesterol), regular clinical monitoring of weight, and in some cases, lens examinations at regular intervals.


Q: Can Seroquel 50 mg impact a person's ability to drive or operate machinery?

Yes, regulatory documents issue a formal warning for the Potential for Cognitive and Motor Impairment. Because the drug can cause drowsiness, dizziness, or impaired coordination, official guidance includes a warning that patients should be certain of how the drug affects them before engaging in activities like operating hazardous machinery.


Q: Is the difference between Seroquel immediate-release (IR) and extended-release (XR)?

The key difference is in administration: Immediate-Release (IR) tablets are taken several times a day (in divided doses) and can be taken with or without food. Extended-Release (XR) tablets are designed for once-daily dosing, usually in the evening, and must be taken without food or with only a light meal to ensure proper drug release.


Q: Does taking Seroquel have a documented effect on the body's ability to regulate temperature?

Yes, regulatory information documents that this class of medication has been associated with disrupting the body's ability to decrease core body temperature. This means that patients should be aware of factors such as strenuous exercise, dehydration, and exposure to extreme heat.


Q: Are there studies that describe Seroquel's impact on concentration or memory?

The official label includes a warning about the Potential for Cognitive and Motor Impairment due to the drug’s effects on the central nervous system. The common side effects of somnolence (drowsiness) and fatigue also noted in official documents can indirectly affect concentration and memory.


Q: What is the official research status of Seroquel's effectiveness for symptoms of bipolar depression?

Based on clinical trial evidence, Seroquel is officially indicated (approved for use) for the treatment of depressive episodes associated with bipolar disorder. This indication is a primary finding derived from the research submitted to regulatory authorities.


Q: What are the potential signs of an overexposure to Seroquel?

Official prescribing information describes signs of overdosage as an exaggeration of the drug's known effects. These potential signs include severe drowsiness, sedation, hypotension (low blood pressure), and tachycardia (rapid heart rate). Extreme overdosage has been associated with coma and death.


Q: Are there any documented drug-drug interactions that are considered life-threatening with Seroquel?

Regulatory information advises strict caution or contraindication for certain combinations. Specifically, the co-administration with other drugs that prolong the QT interval (an effect on heart rhythm) is noted due to the risk of serious, potentially life-threatening cardiac events. Additionally, co-administration with strong CYP3A4 enzyme inhibitors significantly increases drug exposure, requiring mandatory dose adjustments.


Q: What research is available on the long-term metabolic consequences of Seroquel use?

Official labeling documents that the class of medications Seroquel belongs to is associated with significant metabolic changes over time. These changes, which are monitored long-term, include the risk of hyperglycemia (high blood sugar) and the development of diabetes mellitus, dyslipidemia (abnormal cholesterol/triglycerides), and weight gain.


Q: Is it common for Seroquel to be prescribed alongside antidepressant medications?

Yes, official documents state that Seroquel is indicated (approved for use) as an adjunct treatment (an add-on medication) to antidepressant therapy for patients experiencing Major Depressive Disorder (MDD).

How should Seroquel 50% be stored and disposed of?

Official Storage and Disposal Requirements

Seroquel (quetiapine fumarate) must be stored according to regulatory labeling to maintain stability. The tablets are required to be kept at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F). The product must be protected from freezing, heat, moisture, and direct light. Always keep the medication in its tightly closed original container and securely stored out of the reach and sight of children.

For disposal of unused or expired tablets, the official guidance recommends using a drug take-back location or authorized collector. Seroquel is not on the FDA's flush list. If a take-back program is unavailable, follow the procedure for non-flush list medicines, which includes mixing the product with an unappealing substance before disposal in household trash. It is mandatory to avoid release to the environment, including drains and watercourses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Seroquel 50% found in:

A-Z Index: